TSE:4507Pharmaceuticals
The Bull Case For Shionogi (TSE:4507) Could Change Following Japan’s First Pediatric ADHD Digital Therapeutic Launch
Shionogi & Co., Ltd. has begun sales in Japan of EndeavorRide, the first approved digital therapeutic support app for pediatric ADHD, following favorable Phase 3 trial results in 164 patients aged 6–17.
By introducing a regulated, app-based treatment that targets prefrontal cortex activity via Akili’s SSME (TM) technology, Shionogi is extending ADHD care beyond traditional psychosocial and drug therapies.
We will now explore how the launch of this first-in-Japan pediatric ADHD digital...